title: Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial.
abstract: BACKGROUND
  Increased thrombogenicity and smooth muscle cell proliferative response induced by the metal struts compromise the advantages of coronary stenting. The objective of this randomized, multicenter study was to assess whether a reduced strut thickness of coronary stents is associated with improved follow-up angiographic and clinical results.
  
  
  RESULTS
  A total of 651 patients with coronary lesions situated in native vessels >2.8 mm in diameter were randomly assigned to receive 1 of 2 commercially available stents of comparable design but different thickness: 326 patients to the thin-strut stent (strut thickness of 50 microm) and 325 patients to the thick-strut stent (strut thickness of 140 microm). The primary end point was the angiographic restenosis (>/=50% diameter stenosis at follow-up angiography). Secondary end points were the incidence of reinterventions due to restenosis-induced ischemia and the combined rate of death and myocardial infarctions at 1 year. The incidence of angiographic restenosis was 15.0% in the thin-strut group and 25.8% in the thick-strut group (relative risk, 0.58; 95% CI, 0.39 to 0.87; P=0.003). Clinical restenosis was also significantly reduced, with a reintervention rate of 8.6% among thin-strut patients and 13.8% among thick-strut patients (relative risk, 0.62; 95% CI, 0.39 to 0.99; P=0.03). No difference was observed in the combined 1-year rate of death and myocardial infarction.
  
  
  CONCLUSIONS
  The use of a thinner-strut device is associated with a significant reduction of angiographic and clinical restenosis after coronary artery stenting. These findings may have relevant implications for the currently most widely used percutaneous coronary intervention.
authors.affiliation: Deutsches Herzzentrum, Munich, Germany. kastrati@dhm.mhn.de
authors.forename: A
authors.initials: A
authors.lastname: Kastrati
authors.forename: J
authors.initials: J
authors.lastname: Mehilli
authors.forename: J
authors.initials: J
authors.lastname: Dirschinger
authors.forename: F
authors.initials: F
authors.lastname: Dotzer
authors.forename: H
authors.initials: H
authors.lastname: Schühlen
authors.forename: F J
authors.initials: FJ
authors.lastname: Neumann
authors.forename: M
authors.initials: M
authors.lastname: Fleckenstein
authors.forename: C
authors.initials: C
authors.lastname: Pfafferott
authors.forename: M
authors.initials: M
authors.lastname: Seyfarth
authors.forename: A
authors.initials: A
authors.lastname: Schömig
mesh_terms: D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging* / Q000601:surgery*; D003331:Coronary Vessels / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D006439:Hemodynamics; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D012306:Risk; D018570:Risk Assessment; D015607:Stents / Q000009:adverse effects* / Q000592:standards; D015996:Survival Rate; D016896:Treatment Outcome